Welcome to Europe-Taiwan Biotech Association (ETBA). ETBA aims to enhance the connections and collaborations between Taiwan and European countries in the areas of biotechnology, pharmaceuticals, and medical technology.

We believe the advancements in these fields will contribute significantly to improve the qualities of life and make our planet a better place to live.

Currently ETBA is run by dedicated teams located in Switzerland, Germany, France, Spain, United Kingdom, Netherlands and Taiwan, serving our association members spreading across over 20 countries.

Upcoming Events

2022 Switzerland-Taiwan Biotech Leaders’ Forum

Date/Time: 19 Nov 2022

13:00-16:00 (CET) ; 20:00-23:00 (Taiwan Time)

Venue: University Hospital Basel, Switzerland / Online

ETBA is hosting the 2022 Switzerland-Taiwan Biotech Leaders’ Forum in Basel, Switzerland. With ETBA’s goal to facilitate the collaboration between Taiwan and Switzerland in the biopharma sector, the forum focuses on leveraging partnerships to accelerate the costly and time-consuming drug development in biopharma, as well as the pipeline generation through proven, commercially launched assets.
This half-day event features two inspiring keynote speakers who will give an overview of the landscape of external partnerships across the large-scale pharma and small-/medium-sized biotech companies. Followed by a talk that highlights how novel partnership strategies can be developed as part of business models. We believe this Forum will provide an opportunity to share experiences and develop professional networks for future collaborations.

Partner’s Event

2022 Emerging RNA Drugs and Smart Manufacturing in Precision Medicine Forum

Date/Time: 2022/3/17 (Thursday)

16:00-18:00(TW) 9:00-11:00 (CET)

Venue: Online

RNA-based therapeutics are novel medications, serving as next- generation alternatives and offering unique opportunities to treat a broad scope of diseases with a significant success in cancer over the past decade. In addition, from perspectives on pandemic prevention, mRNA vaccines have been developed as well and widely harnessed against COVID-19. Therefore, there is growing interest drawn globally in this new class of therapeutics.

Although development of RNA drugs faces unparalleled challenges, many strategies have been built to improve RNA metabolic stability and intracellular delivery, of which smart manufacturing is the most critical when it comes to clinical development and navigating the regulatory pathways. To expedite the biomedical development with COVID’s viral evolution, facilitate networking and in turn co-development between the participants, we are going to have pharmaceutical experts and professionals in this forum sharing the latest trends in this emerging field.